Exploiting drugs that inhibit macrophage recruitment into tumors [48], harnessing macrophage FcγR-mediated processing for local delivery of antibody-drug conjugates [49], or macrophage mediated drug delivery to the tumor’s extracellular matrix [49] may prove beneficial in slowing tumor progression. This evidence concerns the gene FCGR2A and neoplasm.